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Inflammatory bowel disease (IBD) mainly con-
sists of two disorders, ulcerative colitis and 
Crohn’s disease (CD), with a combined preva-
lence of 150–200 cases per 100,000 in West-
ern countries (Shanahan, 2002; Loftus, 2004). 
The abnormal inflammatory response observed 
in IBD requires interplay between host genetic 
factors and the intestinal microbiota (Podolsky, 
2002; for review see Strober et al., 2007). The 
role of the microbiota in IBD development is 
highlighted with the following observations: in 
CD patients, postsurgical exposure of the ter-
minal ileum to luminal contents is associated 
with increased inflammation, and diversion of 
the fecal stream is associated with improvement 
(Rutgeerts et al., 1991); some IBD patients im-
prove upon antibiotic treatment (Sartor, 2004; 
Sands, 2007); the severity of colitis in multiple 
animal models is decreased by the administra-
tion of antibiotics; and no sign of colitis is ob-
served  when  those  animals  are  in  germ-free 
conditions (for review see Sartor, 2008).
Two broad hypotheses have arisen regard-
ing the role of the intestinal microbiota in the 
pathogenesis of IBD. Several lines of evidence 
support the notion that IBD results from an ex-
cessive  immune  response  to  gut  commensal 
organisms (for review see Strober et al., 2007). 
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Abnormal expression of CEACAM6 is observed at the apical surface of the ileal epithelium 
in Crohn’s disease (CD) patients, and CD ileal lesions are colonized by pathogenic adherent-
invasive Escherichia coli (AIEC). We investigated the ability of AIEC reference strain LF82 
to colonize the intestinal mucosa and to induce inflammation in CEABAC10 transgenic mice 
expressing human CEACAMs. AIEC LF82 virulent bacteria, but not nonpathogenic E. coli  
K-12, were able to persist in the gut of CEABAC10 transgenic mice and to induce severe 
colitis with reduced survival rate, marked weight loss, increased rectal bleeding, presence of 
erosive lesions, mucosal inflammation, and increased proinflammatory cytokine expression. 
The colitis depended on type 1 pili expression by AIEC bacteria and on intestinal CEACAM 
expression because no sign of colitis was observed in transgenic mice infected with type 1 
pili–negative LF82-fimH isogenic mutant or in wild-type mice infected with AIEC LF82 
bacteria. These findings strongly support the hypothesis that in CD patients having an 
abnormal intestinal expression of CEACAM6, AIEC bacteria via type 1 pili expression can 
colonize the intestinal mucosa and induce gut inflammation. Thus, targeting AIEC adhesion 
to gut mucosa represents a new strategy for clinicians to prevent and/or to treat ileal CD.
© 2009 Carvalho et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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numbers  of  mucosa-associated  Escherichia  coli  are  observed 
(Darfeuille-Michaud et al., 1998; Martin et al., 2004; Conte 
et al., 2006; Baumgart et al., 2007; Kotlowski et al., 2007; 
Sasaki et al., 2007). This overgrowth of E. coli can result from 
host-mediated inflammation or abnormal expression of mol-
ecules acting as receptors for bacterial adhesion. In CD pa-
tients with ileal involvement of the disease, we recently 
reported an abnormal ileal expression of carcinoembryonic 
antigen-related cell adhesion molecules (CEACAMs) 5 and 6 
(Barnich et al., 2007) and showed that only CEACAM6 acts 
as a receptor for pathogenic E. coli. These bacteria, called ad-
herent-invasive E. coli (AIEC), colonize the ileal mucosa of 
CD patients (Darfeuille-Michaud et al., 2004). They are able 
to adhere to and invade intestinal epithelial cells and to sur-
vive and highly replicate within macrophages, leading to the 
secretion of high amounts of TNF (Boudeau et al., 1999; 
Glasser et al., 2001). Interestingly, in vitro studies demon-
strated that CEACAM6 expression is increased in cultured 
However, the disease could result from a problem in the 
composition of the microflora leading to generalized or local-
ized dysbiosis. Thus, a breakdown in the balance between 
putative species of “protective” versus “harmful” intestinal 
bacteria has been reported and may promote inflammation.   
A low proportion of Faecalibacterium prausnitzii on resected ileal 
Crohn mucosa is associated with endoscopic recurrence at   
6 mo, and this bacteria has antiinflammatory properties 
(Tamboli et al., 2004; Sokol et al., 2008). In addition, host-
mediated inflammation in response to a pathogen infection 
can disrupt the intestinal microbiota and shift the balance be-
tween the protective microbiota and the pathogen in favor of 
the pathogen, as seen with Citrobacter rodentium infection pro-
moting  the  overgrowth  of  Enterobacteriaceae  (Lupp  et  al., 
2007) and with Salmonella Typhimurium infection (Stecher 
et al., 2007). In patients with CD and ulcerative colitis, high 
concentrations of bacteria forming a biofilm on the surface   
of the gut mucosa (Swidsinski et al., 2002) and increased 
Figure 1.  AIEC LF82 bacterial colonization and persistence in mouse intestine according to CEACAM expression. (A and B) Quantification of 
AIEC LF82 (A) or E. coli K-12 MG1655 (B) in the feces of WT (wt, white triangles) or CEABAC10 (tg, black triangles) mice receiving 0.25% DSS in drinking 
water after oral infection with 109 bacteria at day 0. (C) Quantification of colonic mucosal-associated AIEC LF82 bacteria at day 7 after oral infection. The 
quantification for each mouse (symbols) and the median (bars) is expressed as CFU/g of feces or CFU/mg of organ tissue. (D) Confocal microscopy analy-
sis of colonic section at day 7 after infection from WT or transgenic mice infected with AIEC LF82. CEACAM6 expression was detected using anti-
CEACAM6 monoclonal antibody and a Cy3-conjugated anti–mouse IgG. AIEC LF82 bacteria were detected using anti-O83 rabbit antibody and a 
FITC-conjugated anti–rabbit IgG. Arrow shows colocalization (yellow staining) between CEACAM6 and bacteria. WT FVB/N mice: E. coli K-12 MG1655 in-
fected (n = 13), AIEC LF82 infected (n = 9); CEABAC10 transgenic FVB/N mice: E. coli K-12-MG1655 (n = 13), AIEC LF82-infected (n = 15). Results shown 
here are representative of three separate colonization experiments. *, P < 0.05; ***, P < 0.001. Bars, 50 µm.JEM VOL. 206, September 28, 2009 
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significantly  (P  =  0.013)  more  AIEC  LF82  bacteria  were 
found in stools of mice expressing human CEACAMs (3.0 × 
108 CFU/g of feces) compared with WT mice (8.5 × 107 
CFU/g of feces; Fig. 1 A). At day 6, the differences between 
WT and transgenic mice were even higher and statistically 
more significant (P = 0.002) because the median number of 
AIEC LF82 bacteria found in stools of transgenic mice was 
1.1 × 106 CFU/g of feces compared with 1.3 × 104 CFU/g 
of feces for WT mice (Fig. 1 A). It is of note that at day 6 after 
infection, 10/10 of the CEABAC10 mice still presented more 
than 105 CFU of AIEC LF82 per gram of feces compared 
with only 3/13 for WT mice. When experiments were per-
formed with the nonpathogenic E. coli K-12, no differences in 
the numbers of bacteria in the stools were encountered be-
tween WT and transgenic mice (Fig. 1 B). Bacteria counts 
rapidly decreased in the feces of WT or transgenic mice be-
cause only 3.1 × 106 CFU/g of feces and 2.1 × 106 CFU/g of 
feces, respectively, were found at day 1 after infection. At day 
3 after infection, the number of E. coli K-12 bacteria present 
in feces of infected mice was <105 CFU/g of feces.
To confirm AIEC LF82 colonization, we determined the 
number of colonic mucosa-associated bacteria to investigate 
whether the presence of AIEC LF82 bacteria in the feces   
intestinal epithelial cells not only after IFN- or TNF stimu-
lation (Fahlgren et al., 2003) but also after infection with 
AIEC bacteria, indicating that AIEC could promote their 
own colonization in CD patients (Barnich et al., 2007). In 
the present paper, using transgenic CEABAC10 mice har-
boring a bacterial artificial chromosome that contains part of 
the human CEA family gene cluster, including complete 
human CEACAM3, CEACAM5 (CEA), CEACAM6, and 
CEACAM7 genes (Chan and Stanners, 2004), we investi-
gated whether LF82 bacteria isolated from a CD patient can 
colonize the intestinal mucosa as a result of CEACAM ex-
pression and whether AIEC LF82 colonization could lead to 
the development of gut inflammation.
RESULTS
Intestinal expression of human CEACAMs allowed AIEC 
LF82 gastrointestinal (GI) colonization and persistence
WT FVB/N and CEABAC10 mice were orally challenged 
with 109 bacteria, and the level of bacteria in the stools was 
followed to evaluate bacterial colonization rate. The analysis 
of the presence of AIEC bacteria in the stools revealed that 
there were no differences in bacterial counts between WT 
mice and transgenic mice until day 2 after infection. At day 3, 
Figure 2.  AIEC LF82 bacteria induced clinical symptoms of colitis in CEABAC10 transgenic mice. (A–F) AIEC LF82 infections were performed in 
WT (A–C) and in CEABAC10 (D–F) mice. Shown is evolution of body weight (A and D), survival rate (B and E), and DAI score ascertained at day 7 after in-
fection (C and F) of mice orally challenged at day 0 with CMC alone (black circles), with CMC containing 109 E. coli K-12 MG1655 bacteria (white trian-
gles), or with CMC containing 109 AIEC LF82 bacteria (white squares). (G) Quantification of AIEC LF82 at day 7 after infection in the liver and spleen. WT 
FVB/N mice: CMC alone (n = 11), E. coli K-12 MG1655 infected (n = 7), AIEC LF82 infected (n = 14); CEABAC10 transgenic FVB/N mice: CMC alone (n = 9), 
E. coli K-12 MG1655 infected (n = 11), AIEC LF82 infected (n = 15). Shown here are representative body weight evolution, survival rate, and DAI of three 
separate experiments. Horizontal bars represent medians. Error bars represent SEM. **, P < 0.01; ***, P < 0.001 (compared with noninfected mice).2182 CEACAM INTESTINAL EXPRESSION AND AIEC COLONIZATION | Carvalho et al.
DAI score of transgenic mice infected with AIEC LF82 bac-
teria was significantly higher at day 6 (5.4 ± 0.3) compared 
with noninfected mice (0.8 ± 0.5; P < 0.001) or those in-
fected with E. coli K-12 (0.3 ± 0.3; P < 0.001; Fig. 2 F). 
AIEC colonization in WT mice over a 14-d period did not 
decrease body weight or result in mortality. Similar results 
were observed in CEABAC10 mice administered with K-12 
bacteria (unpublished data). In addition, dissemination of 
AIEC LF82 bacteria was observed in the liver and the spleen 
of three and four transgenic mice, respectively (Fig. 2 G), but 
in no infected WT mice.
To confirm the involvement of human CEACAM6 in 
AIEC LF82 colonization and induction of inflammation in 
transgenic mice, AIEC-infected transgenic mice received in-
traperitoneal injections of anti-CEACAM6 monoclonal anti-
body 9A6 1 d before infection and at days 0, 1, and 3 after 
infection. The resulting blockade of CEACAM6 receptor 
significantly decreased AIEC LF82 colonization until the 
mice  received  anti-CEACAM6  monoclonal  antibodies   
(Fig. 3 A). Significantly lower DAI scores and significant 
gains in body weight were also observed at day 6 after infec-
tion (Fig. 3, B and C). Overall, these results therefore indi-
cate that among the various human CEACAMs expressed by 
transgenic mice, CEACAM6 is required to allow CD-associ-
ated AIEC bacteria to colonize the intestine and to induce 
clinical symptoms of colitis.
Histological analyses of colonic tissues were performed at 
day 7 after infection to evaluate the degree of inflammation. 
In WT mice infected with AIEC LF82 bacteria, a slight poly-
nuclear infiltration was observed but colonic mucosa was nor-
mal, with the crypts being straight, well defined, and sitting 
on the muscularis mucosa (Fig. 4 A). In addition, the histo-
logical score was not significantly different between nonin-
fected, E. coli K-12–infected, and AIEC LF82-infected mice 
(Fig. 4 B). In contrast, histological colonic sections of AIEC 
LF82-infected transgenic mice showed hemorrhagic walls 
with multiple ulcerations, mucosal edema, neutrophil infiltra-
tions with transmural involvement, and presence of large ero-
sion areas (Fig. 4 C). Also, the histological score was greatly 
correlated with mucosal colonization of the GI tract. At day 
7 after infection, AIEC bacteria were not detected in 12 out 
of 13 colonic samples of WT mice (Fig. 1 C). In contrast, we 
found that a majority of transgenic mice (8/13) harbored 
colon-associated AIEC LF82 bacteria, and confocal microscopy 
examination of colonic sections stained for CEACAM6 
showed that AIEC bacteria colocalized with CEACAM6 ex-
pression (Fig. 1 D).
AIEC LF82 GI colonization induced severe colitis in mice 
expressing human CEACAMs
To analyze the consequences of AIEC LF82 colonization, we 
recorded the body weight loss, survival rate, and disease ac-
tivity index (DAI) score of WT mice and CEABAC10 mice 
orally challenged with 109 bacteria. None of the WT mice 
challenged with AIEC LF82 or E. coli K-12 bacteria devel-
oped bloody diarrhea or appeared ill. There was a similar 
evolution in body weight in both infected and noninfected 
mice and no mortalities in either group (Fig. 2, A and B). 
None of the E. coli K-12– and LF82-infected WT mice pre-
sented clinical symptoms of colitis, and no significant differ-
ence in DAI scores was observed between noninfected,   
E. coli K-12–infected, and LF82-infected WT mice (Fig. 2 C). 
In contrast, clinical symptoms of colitis were observed in 
CEABAC10 mice orally challenged with AIEC LF82. At day 
2, a significant (P < 0.01) decrease in body weight of mice 
infected with AIEC LF82 (87.4 ± 2.0%) was observed com-
pared with noninfected transgenic mice (96.0 ± 1.6%) or 
mice infected with E. coli K-12 (92.5 ± 1.5%; Fig. 2 D), a 
difference which persisted until the end of the experiment. 
The severity of the disease induced by AIEC infection in 
transgenic mice was confirmed by a high mortality rate. In-
fection with AIEC LF82 bacteria induced a strongly reduced 
survival rate from day 2 (Fig. 2 E) and, at day 7 after infec-
tion, only 20% of mice survived, whereas no mortality was 
observed in noninfected transgenic mice or in those infected 
with E. coli K-12 bacteria. Increased clinical symptoms of 
colitis were observed in transgenic mice orally challenged 
with AIEC LF82 compared with E. coli K-12 bacteria. The 
Figure 3.  Intraperitoneal administration of anti-CEACAM6 monoclonal antibody 24 h before infection and at days 0, 1, and 3 after infec-
tion prevents colonization and clinical symptoms of colitis in AIEC LF82-infected CEABAC10 transgenic mice. (A–C) Evolution of the number of 
AIEC LF82 in the feces (A), of DAI score ascertained at days 3 and 6 after infection (B), and of body weight (C) of transgenic mice orally challenged at day 
0 with 109 AIEC LF82 bacteria. Horizontal bars represent medians. CEABAC10 transgenic FVB/N mice: AIEC LF82 infected (n = 5; black triangles); AIEC LF82 
infected after intraperitoneal injection of anti-CEACAM6 antibody (n = 5; black circles). Two experiments were performed independently. Shown here are 
colonization, DAI, and body weight evolution of one representative experiment. Error bars represent SEM. *, P < 0.05; **, P < 0.01.JEM VOL. 206, September 28, 2009 
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the LF82-fimH mutant in the stools (2.2 × 107 CFU/g of 
feces) compared with WT AIEC LF82 bacteria (3.0 × 108 
CFU/g of feces) was observed at day 3 after infection (P = 
0.001). At day 6 after infection, a 2-log difference was ob-
served between WT LF82 bacteria and type 1 pili–negative 
LF82-fimH mutant. In agreement with these results, trans-
genic mice receiving the LF82-fimH mutant, unlike those 
infected with WT AIEC LF82 bacteria, had a body weight 
similar to that observed for noninfected mice from day 5 after 
infection (Fig. 5 B). In addition, an 85% survival rate was ob-
served for AIEC LF82-fimH mutant infected mice, com-
pared with only 20% for AIEC LF82 infected mice at day 7 
after infection (Fig. 5 C). Also, mice infected with the AIEC 
LF82-fimH isogenic mutant did not present any significant 
difference in the DAI score compared with noninfected mice 
(Fig. 5 D). Colonic examination revealed that histological 
damages observed in AIEC LF82-infected transgenic mice 
were no longer observed in mice infected with the LF82-
fimH mutant (Fig. 6 A). Indeed, these mice presented nor-
mal colonic histological structures with little infiltration of 
inflammatory cells; the colonic histological score was signifi-
cantly (P = 0.003) decreased for mice infected with the 
LF82-fimH  isogenic  mutant  (6.8  ±  1.1)  compared  with 
mice infected with AIEC LF82 bacteria (11.0 ± 0.4; Fig. 6 B). 
increased in transgenic mice infected with LF82 (11.0 ± 0.4) 
compared with noninfected mice (3.0 ± 0.7) or mice infected 
with E. coli K-12 (3.0 ± 0.8), and the differences were highly 
statistically significant (P < 0.001; Fig. 4 D). Epithelial damage 
occurred in all areas of the colonic mucosa and the infiltrated 
immune cells were mostly polynuclear cells. In addition, some 
cryptic abscesses were observed in transgenic mice infected 
with AIEC LF82 but not in those infected with E. coli 
MG1655. These findings demonstrate that mice expressing 
human CEACAMs are susceptible to AIEC LF82 oral infec-
tion and develop severe clinical symptoms of colitis.
AIEC LF82 colonization and induced colitis is dependent  
on type 1 pili expression
To investigate the role of type 1 pili in AIEC bacterial colo-
nization, CEABAC10 transgenic mice were challenged with 
AIEC LF82-fimH isogenic mutant, which did not produce 
type 1 pili but was still able to synthesize functional flagella 
(unpublished data). Analysis of the presence of AIEC LF82 
bacteria or the LF82-fimH mutant in the stools revealed that 
at day 2 after infection there was a statistically significant 4.5-
fold decrease (P = 0.033) in LF82-fimH mutant (7 × 107 
CFU/g of feces) compared with WT AIEC LF82 bacteria 
(3.2 × 108 CFU/g of feces; Fig. 5 A). A 13.6-fold decrease in 
Figure 4.  Intestinal colonization by AIEC LF82 bacteria causes severe histopathological damage in colonic mucosa. (A–D) Hematoxylin/eosin/
safran staining of colonic tissue sections obtained at day 7 after infection from WT mice (A) or CEABAC10 transgenic mice (C), noninfected or infected 
with E. coli K-12 MG1655 or with AIEC LF82 bacteria (magnification, 100×). Histopathological scoring for several parameters of colonic inflammation was 
performed for WT mice (B) or CEABAC10 transgenic mice (D), noninfected or infected with 109 E. coli K-12 MG1655 or with AIEC LF82 bacteria. WT FVB/N 
mice: CMC alone (n = 11), E. coli K-12 MG1655 infected (n = 12), AIEC LF82 infected (n = 14); CEABAC10 transgenic FVB/N mice: CMC alone (n = 9), E. coli 
K-12 MG1655 infected (n = 11), AIEC LF82 infected (n = 15). Shown here are representative histological scores of two separate experiments. Error bars 
represent SEM. ***, P < 0.001 compared with noninfected mice. Bars, 100 µm.2184 CEACAM INTESTINAL EXPRESSION AND AIEC COLONIZATION | Carvalho et al.
et al., 2007; Sasaki et al., 2007; Eaves-Pyles et al., 2008). The 
latter are able to adhere to and invade intestinal epithelial cells 
and to replicate within macrophages, eliciting a strong pro-
inflammatory response through TNF secretion (Darfeuille- 
Michaud et al., 1998; Boudeau et al., 1999; Glasser et al., 
2001). A possible explanation for the increased number of 
AIEC bacteria associated with ileal mucosa is the increased 
expression of CEACAM6 on the brush border of ileal en-
terocytes in CD patients because our previous in vitro studies 
suggested that CEACAM6 can act as a receptor for AIEC 
binding to the intestinal mucosa (Barnich et al., 2007). In this 
paper, we analyzed through in vivo experiments whether 
CEACAM expression can lead to abnormal colonization by 
AIEC bacteria and to the development of gut inflammation.
To mimic abnormal expression of CEACAM6 observed 
in CD patients, we used the transgenic CEABAC10 mouse 
model expressing human CEACAMs (Chan and Stanners, 
2004). Oral challenge of these mice with the AIEC reference 
strain LF82 induced body weight loss, diarrhea, rectal bleed-
ing, and a greatly reduced survival rate of only 20% at day 7 
after infection. Infected transgenic CEABAC10 mice, but 
not WT mice, presented severe gut inflammation with in-
creased proinflammatory cytokines IL-1, IL-6, and IL-17 
mRNA levels, decreased antiinflammatory cytokine IL-10 
mRNA levels, and histopathological damage of gut mucosa. 
As the lesions were restricted to the colonic mucosa, we 
therefore further analyzed the discrepancy in the site of   
Finally, significantly increased levels of IL-1, IL-6, and IL-17 
mRNAs (5.5-fold, 3.4-fold, and 6.1-fold, respectively) and 
significantly  decreased  levels  of  IL-10  mRNAs  (5.6-fold) 
were observed in colonic specimens of CEABAC10 mice 
infected with AIEC LF82 bacteria compared with those of 
noninfected mice (Fig. 6, C–F). In contrast, such variations 
in cytokine levels were not observed after infection with the 
LF82-fimH isogenic mutant. Altogether, these results rein-
force the role of type 1 pili in AIEC LF82 colonization and 
reveal that only fully virulent AIEC LF82 bacteria can induce 
colitis in CEABAC10 mice by increasing the expression of 
proinflammatory cytokines.
DISCUSSION
Two broad hypotheses have emerged regarding the patho-
genesis of IBD. One speculates that primary dysregulation of 
the mucosal immune system leads to excessive immunologi-
cal responses to normal microflora and the other suggests that 
changes in the composition of gut microflora elicit patholog-
ical responses from the normal mucosal immune system (for 
review see Strober et al., 2007). In the ileal involvement of 
CD, changes in mucosa-associated microbiota have been ob-
served, in particular a decrease in F. prausnitzii, bacteria with 
antiinflammatory properties (Sokol et al., 2008), and an in-
crease in pathogenic E. coli (Neut et al., 2002; Swidsinski 
et al., 2002; Darfeuille-Michaud et al., 2004; Martin et al., 
2004; Mylonaki et al., 2005; Conte et al., 2006; Kotlowski   
Figure 5.  AIEC LF82 colonization via type 1 pili expression induce clinical symptoms of colitis in CEABAC10 transgenic mice. (A) Quantification 
of AIEC LF82 bacteria (black triangles) or type 1 pili–negative AIEC LF82-fimH mutant (white triangles) in the feces of CEABAC10 mice after oral infection 
with 109 bacteria at day 0. Each symbol represents one mouse and the horizontal bars represent the medians. (B and C) Evolution of body weight (B) and 
survival rate (C) of CEABAC10 transgenic mice orally challenged at day 0 with CMC alone (black circles), CMC containing 109 AIEC LF82 bacteria (white 
squares), or CMC containing 109 AIEC LF82-fimH bacteria (white triangles). (D) DAI score ascertained for CEABAC10 transgenic mice that were nonin-
fected, infected with AIEC LF82-fimH bacteria, or infected with AIEC LF82 bacteria at day 7 after infection. CEABAC10 transgenic FVB/N mice: CMC alone 
(n = 9), AIEC LF82-fimH infected (n = 14), AIEC LF82 infected (n = 15). Shown here are representative body weight evolution, survival rate, and DAI of 
three separate experiments. Error bars represent SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (compared with mice infected with AIEC LF82-fimH).JEM VOL. 206, September 28, 2009 
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CEACAM6 and that the adhesion of AIEC bacteria is man-
nose dependent (Barnich et al., 2007). Among the human 
CEACAM  molecules  expressed  in  the  GI  tract  of  CEA-
BAC10 mice or CD patients, we show here that in transgenic 
mice expressing human CEACAMs, CEACAM6 plays a key 
role. Indeed, intraperitoneal administration of anti-CEACAM6 
monoclonal antibodies, by blocking the CEACAM6 recep-
tor, resulted in significant decreases in AIEC LF82 coloniza-
tion and DAI scores.
As a general rule, colonization of the gut mucosa by bac-
teria can elicit gut inflammation, but this is not observed for 
Campylobacter jejuni, which failed to induce an inflammatory 
response (Rinella et al., 2006; Mansfield et al., 2007). In the 
present study, we observed for AIEC bacteria a strict correla-
tion between colonization and development of inflamma-
tion. Indeed, in WT mice orally challenged with AIEC LF82, 
we observed neither colonization nor any sign of gut inflam-
mation. In contrast, when CEABAC10 mice were challenged 
lesions between mice and CD patients because AIEC bacteria 
are associated with ileitis (Darfeuille-Michaud et al., 2004). 
Western  blot  analysis  of  CEACAMs  expression  in  CEA-
BAC10  transgenic  mice  indicated  that  CEACAM5  was 
highly expressed in both small intestine and colon, but that 
expression of CEACAM6 was restricted to the colonic mu-
cosa (unpublished data). This confirmed the previously   
reported lack of ceacam6 mRNA in the ileal mucosa of   
CEABAC10 transgenic mice (Chan and Stanners, 2004). 
Thus, in this mouse model challenged with AIEC bacteria, 
the absence of ileal inflammation can be explained by the lack 
of ileal CEACAM6 expression. These results can be corre-
lated with our previous study showing that ileal enterocytes 
from  CD  patients  overexpressed  both  CEACAM5  and 
CEACAM6 and that the AIEC adhesion to the brush border 
of enterocytes was inhibited by CEACAM6 antibodies but 
not by CEACAM5 antibodies. This could be a result of   
the  fact  that  mannose-rich  sugars  are  more  prevalent  on 
Figure 6.  Type 1 pili–dependent AIEC LF82 colonization is required to induce severe histopathological damage and inflammation of colonic 
mucosa. (A) Hematoxylin/eosin/safran staining of colonic tissue sections obtained at day 7 after infection from CEABAC10 transgenic mice noninfected, 
infected with AIEC LF82-fimH isogenic mutant, or infected with AIEC LF82 bacteria (magnification, 100×). (B) Histopathological scoring for several pa-
rameters of colonic inflammation. (C–F) Total RNAs from mouse colon were isolated and IL-1 (C), IL-6 (D), IL-17 (E), and IL-10 (F) mRNA levels were mea-
sured by RT-PCR. CEABAC10 transgenic FVB/N mice: CMC alone (n = 9), AIEC LF82-fimH infected (n = 14), AIEC LF82 infected (n = 15). Shown here are 
representative histological scores of two separate experiments. Error bars represent SEM. *, P < 0.05; **, P < 0.01 (compared with mice infected with AIEC 
LF82-fimH). Bars, 100 µm.2186 CEACAM INTESTINAL EXPRESSION AND AIEC COLONIZATION | Carvalho et al.
to block AIEC adhesion and therefore colonization, such as 
use of probiotics and/or vaccination. Results of probiotic trials 
in CD are mixed (Sartor, 2004). E. coli Nissle 1917 was more 
effective than a placebo in preventing relapse of CD after in-
duction of remission by standard medical therapy (Malchow, 
1997), but no benefit of Lactobacillus GG administered for 1 yr 
could be demonstrated in preventing postoperative relapse of 
symptoms  or  endoscopic  lesions  in  the  neoterminal  ileum 
(Prantera et al., 2002). However, the findings of the present 
study suggest that probiotics, such as yeasts or cell wall man-
noprotein from yeasts, which are very rich in free mannose 
residues, would be a promising strategy to inhibit AIEC colo-
nization in patients expressing CEACAM6 on the ileal mu-
cosa and harboring AIEC bacteria and, therefore, to prevent 
recurrent intestinal inflammation and possibly to treat active 
CD. In addition, E. coli Nissle 1917, which has a strong and 
significant inhibitory effect on adherent-invasive E. coli adhe-
sion and invasion in co-infection and preinfection experi-
ments, could thus be effective for preventive or curative 
probiotic therapy in patients with CD (Boudeau et al., 2003). 
Adhesin-based vaccines may also be effective in the preven-
tion of CD, as previously reported for the prevention of recur-
rent and acute infections of the urogenital mucosa (Langermann 
et al., 1997). It was reported for uropathogenic E. coli that an-
tibodies specifically blocking the binding of FimH to its natu-
ral receptor prevent bacterial colonization and the subsequent 
inflammation  of  the  urinary  tract  (Thankavel  et  al.,  1997; 
Langermann et al., 2000). A vaccine containing a recombinant 
truncated form of FimH adhesin strongly reduced the in vivo 
colonization of the bladder by uropathogenic E. coli in a mouse 
cystitis model (Poggio et al., 2006), suggesting that a similar 
approach could be used to block gut AIEC colonization in 
CD patients expressing CEACAM6. Finally, another strategy 
could be to interrupt pilus assembly and thereby block pilus-
mediated adhesion using pilicides, which are pilus inhibitors 
with AIEC bacteria, both bacterial colonization of the co-
lonic mucosa and severe inflammation were observed. How-
ever, transgenic mice given nonpathogenic E. coli orally had 
no E. coli colonization or gut inflammation. A similar absence 
of colonization and inflammation was also observed when 
the nonpiliated mutant of AIEC LF82, which is unable to 
bind CEACAM6, was orally administered to transgenic mice. 
Overall, these results indicate that for AIEC involvement in 
CD the abnormal expression of CEACAM6 plays a crucial 
role by allowing the bacteria to colonize the gut mucosa and, 
subsequently, to trigger inflammation. It has been recently 
reported that the intrusion of enteropathogens into the gut 
ecosystem can result in the triggering of the host’s inflam-
matory response, which disrupts colonization resistance, as 
reported for C. rodentium and Salmonella enterica serovar 
Typhimurium (Lupp et al., 2007; Stecher et al., 2007). In-
flamed gut might offer altered conditions, such as a change in 
the adhesion sites, that can be exploited by the pathogen but 
not by the commensals. In the AIEC model, it would seem 
that it is not only inflammation that promotes intestinal colo-
nization because we previously observed, using the DSS-in-
jured colon model in WT BALB/c/J mice, that infection 
with AIEC LF82 bacteria significantly worsened colitis but 
this inflammation did not allow the AIEC bacteria to colo-
nize the gut (Carvalho et al., 2008).
The inflammation induced by AIEC infection in CEA-
BAC10 transgenic mice was not observed when mice were 
infected with the AIEC LF82 type 1 pili–negative mutant, 
indicating that the adhesion of AIEC bacteria to the gut mu-
cosa via type 1 pili is essential for the development of inflam-
mation. This result is of great interest because FimH could 
serve as a potent stimulator of the innate immune response 
via interaction with TLR4 independently of LPS (Mossman 
et al., 2008). Also, previous molecular dissections of viru-
lence factor expression in the AIEC LF82 strain suggested 
that LF82 bacteria are highly flagellated and, therefore, highly 
piliated under GI tract conditions as a result of a coregulation 
between expression of flagella and type 1 pili (Barnich et al., 
2003; Claret et al., 2007; Rolhion et al., 2007). The results 
reported in the present study showing that gut inflammation 
is linked to type 1 pili expression by pathogenic E. coli corre-
lates with what was observed with uropathogenic E. coli and 
urinary tract infection (Cegelski et al., 2008).
We know from various models that the binding of adhes-
ins expressed on the bacterial cell surface to defined glycosyl-
ated receptors on the host tissue surface is considered to be an 
initial and critical step in pathogenesis. As AIEC bacteria have 
the ability to colonize the intestinal mucosa, this opens a new 
avenue for therapy such as blocking the interaction between 
type 1 pili and CEACAMs. AIEC adhesion involving type 1 
pili is mediated by recognition of mannose residues by the 
FimH adhesion site located at the tip of the pilus (Ofek et al., 
2000). Recent crystal structure determination of FimH com-
plexed with oligomannose-3 showed the feasibility of using 
natural and engineered mannose antagonists to block bacterial 
invasion (Wellens et al., 2008). Several strategies can be used 
Table I.  DAI assessment
Symptom/score Characteristics
Body weight loss
  0 No loss
  1 1–5% loss of body weight
  2 5–10% loss of body weight
  3 10–20% loss of body weight
  4 >20% loss of body weight
Stool consistency
  0 Normal feces
  1 Loose stool
  2 Watery diarrhea
  3 Slimy diarrhea, little blood
  4 Severe watery diarrhea with blood
Blood in stool
  0 No blood
  2 Presence of blood assessed by Hemoccult II test
  4 Visible bleedingJEM VOL. 206, September 28, 2009 
ARTICLE
2187
Infection of mice. 12-wk-old FVB/N WT or CEABAC10 transgenic male 
mice (body weight, 26–28 g) were pretreated by oral administration of the 
broad-spectrum antibiotic streptomycin (20 mg intragastric per mouse) to 
disrupt normal resident bacterial flora in the intestinal tract (Wadolkowski   
et al., 1988; Stecher et al., 2007) and were orally challenged with 109 bacteria 
24 h later. Because we observed a very wide distribution range of the num-
bers of bacteria in the feces, as shown in Fig. S1 A, we adapted the protocol. 
Animals received the very low dose of 0.25% (wt/vol) of dextran sulfate so-
dium (DSS; molecular mass = 36,000-50,000 daltons; MP Biomedicals) in 
drinking water starting 3 d before infection to increase the accessibility of 
bacteria to the surface of the epithelial layer. The administration of 0.25% DSS 
did not affect the body weight of transgenic mice and did not induce clinical 
symptoms of colitis as assessed by the DAI score (Fig. S1, B and C). When 
mice attained 80% of their initial weight or 7 d after oral bacterial infection, 
they were anesthetized with isoflurane and then euthanized by cervical dislo-
cation. Colon specimens were collected to quantify mucosal-associated bac-
teria, to analyze histological damages, and to perform quantitative RT-PCR. 
Spleen and liver were collected to quantify translocated bacteria. To perform 
anti-CEACAM6 antibody treatment, 500 µg of monoclonal anti-CEACAM6 
9A6 (GENOVAC) were injected intraperitoneally in 200 µl of PBS 24 h be-
fore infection, and at days 0, 1, and 3 after infection.
Colonization evaluation. 1, 2, 3, and 6 d after bacterial infection, fresh fe-
cal pellets (100–200 mg) were collected from individual mice and resuspended 
in PBS. After serial dilution, bacteria were enumerated by plating on LB agar 
medium containing 50 mg/µl ampicillin and 20 mg/µl erythromycin to iso-
late AIEC LF82 bacteria and isogenic mutants, 300 mg/µl or containing ri-
fampicin to isolate K-12 MG1655 bacteria, and incubated at 37°C overnight. 
that target chaperone function by inhibiting pilus biogenesis 
(Svensson et al., 2001; Larsson et al., 2005). In conclusion, the 
results generated by the in vivo studies reported in this paper 
could lead to the development of specific therapies to treat pa-
tients with ileal involvement of CD by targeting AIEC bacte-
rial adhesion to the gut mucosa.
MATERIALS AND METHODS
Bacterial strains and culture. Ampicillin-erythromycin–resistant E. coli 
strain LF82, isolated from a chronic ileal lesion of a CD patient, was used as 
the AIEC reference strain (Darfeuille-Michaud et al., 1998). A nonpiliated 
isogenic mutant AIEC LF82 deleted for the fimH gene and the E. coli K-12 
MG1655 rifampicin-resistant strain (laboratory stock) were also used in this 
study.  Overnight  bacterial  cultures  in  Luria-Bertani  (LB)  broth  without 
shaking at 37°C were harvested by centrifugation at 4,000 g for 15 min. The 
bacterial pellet was resuspended in carboxymethyl cellulose (CMC) at 0.5% 
(wt/vol) in distilled water.
Mice. All mice were housed in specific pathogen-free conditions in the ani-
mal care facility at the University of Auvergne (Clermont-Ferrand, France). 
FVB/N WT mice were purchased from Charles River Laboratories and 
CEABAC10 transgenic mice (heterozygote; Chan and Stanners, 2004) were 
maintained in our animal facilities. WT and transgenic CEABAC10 mice 
were coupled to obtain 50% WT mice and 50% CEABAC10 mice. Mice 
from the same generation were used for experimentation. Animal protocols 
were approved by the Committee for Research and Ethical Issues of the In-
ternational Association for the Study of Pain.
Table II.  Histological grading of intestinal inflammation
Symptom Characteristics
Infiltration of inflammatory cells
  0 Rare inflammatory cells in the lamina propria
  1 Increased numbers of inflammatory cells, including neutrophils in the lamina propria
  2 Confluence of inflammatory cells extending into the submucosa
  3 Transmural extension of the inflammatory cell infiltrate
Infiltration of lamina propria by mononuclear cells
  0 Normal
  1 Moderate
  2 Great
Infiltration of lamina propria by polynuclear cells
  0 Normal
  1 Moderate
  2 Great
Infiltration of epithelium by polynuclear cells
  0 No infiltration
  1 Surface
  2 Inside the crypt
  3 Cryptic abscess
Severity of epithelial damage
  0 Absence of mucosal damage
  1 Lymphoepithelial lesions
  2 Mucosal erosion/ulceration
  3 Extensive mucosal damage and extension through deeper structures of the bowel wall
Surface of epithelial damage
  0 Normal
  1 Focal
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